This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Aurum Labs ( [link] ) is now certified by the Colorado Department of Public Health and Environment (CDPHE) to conduct hemp compliance testing for manufactured industrial hemp products and is in the final stages of Drug Enforcement Agency (DEA) registration. Learn more at [link].
(OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company , (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products.
This change shouldn’t affect most hemp farmers who have no interest in cultivating psychoactive plants; however, it does remove a safety net. Another potential headache for farmers is that analytical laboratories must be registered with the DEA in order to perform compliance testing. What does this mean for hemp farmers?
MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE currently produces multiple commercial CBD oral film products in compliance with the 2018 U.S.Farm Bill and European regulations.
Starting today, US manufacturers and merchants can apply through LegitScript to certify CBD products and websites that are in compliance with USDA, FDA, FTC, and DEA regulations, as well as state-specific laws. LegitScript’s CEO, John Horton, said the program will bring transparency and structure to the CBD industry. “The
Ultimately, while the 2018 Farm Bill clarified that hemp is not a controlled substance – and the Drug Enforcement Administration (“DEA”) has no authority over it – the legislation did not resolve lingering questions related to federal food and drug regulations which protect consumer safety, as overseen by the Food and Drug Administration (“FDA”).
The FDA is currently in an ongoing process evaluating the science and safety of CBD and hemp derivatives in order to determine potential regulatory pathways for hemp. Suggestions on how to best divide responsibilities between the acting agencies (FDA, TTB, and ATF) to avoid duplication of administrative and compliance burdens.
Portland, OR — The Oregon Liquor Control Commission’s compliance and enforcement team was instrumental in the dismantling of an illegal marijuana processing site by local, state and federal law enforcement last week in rural Lane County. See the OSP press release.
Many states are now scrambling to close legal loopholes in their drug laws to bring delta-8 into regulatory compliance. But my contacts at the American Herbal Products Association, as well as the DEA (Drug Enforcement Administration) and the American Western Hemp Professionals, and the U.S. But how long will that legal status last?
As a result, labs that have received a state license to test either medical or recreational cannabis have historically been denied a DEA Schedule I license to test hemp under the 2018 Farm Bill. This must be repeated per batch analyzed by the lab on an ongoing basis as part of the lab’s QAQC program (internal) and state compliance (external).
Learn from the experts in the industry The cannabis market is ever-changing, and at CannMed 23 you will have the opportunity to learn from experts in cannabis science, medicine, cultivation, and safety testing who are on the leading edge. Special attention will also be paid to the growing problem of lab shopping.
It seems completely backwards that an unregulated product that gets people “high” and is synthesized in a lab can be sold at gas stations and smoke shops but naturally derived Delta 9-THC must go through rigorous safety testing and can only be sold and handled by licensed companies.
Seq (1970) and Drug Enforcement Administration’s (“DEA”) clutches, 2019 hemp production and sales exploded. Steve represents entities, governments and individuals in choosing a structure, preparing and submitting license application, regulation, compliance and litigation, and drafting legislation. Budgeted at $6.1
Marihuana SafetyCompliance Facility. These licensees must secure registration from the DEA within 90 days of being issued their MRA license. Marihuana Event Organizer. Marihuana Microbusiness. Class A Marihuana Microbusiness. Marihuana Processor. Marihuana Retailer. Marihuana Secure Transporter. Temporary Marihuana Event.
Such actions by the federal will create some very difficult paths because of policy distinctions arising from individual rights, public protections, commercial activities, health and safety, use of resources, etc.]. Will the mandate for the DEA be changed to oversee another special agricultural legal crop or a medicine ?
Cannabis businesses that are ill-prepared for these regulatory requirements risk facing litigation, enforcement actions, fines or penalties, and negative publicity, while those taking a proactive approach to compliance may find opportunities to mitigate and even monetize those risks.
9 Even under the Obama-era policy, Weedmaps might still be exposing itself to federal prosecution because it is not “demonstrably in compliance with [California’s] strong and effective. Even then, publishers should require that any cannabis-business certify its compliance with state and local laws. FOOTNOTES. & Prof. 47 U.S.C. §
Drug Enforcement Administration (the “DEA”), the U.S. state and federal law to U.S. hemp (including CBD) products and the scope of any regulations by the U.S. Food and Drug Administration (the “FDA”), the U.S. Federal Trade Commission (the “FTC”), the U.S. Patent and Trademark Office (the “USPTO”), the U.S. hemp industry in the U.S.,
Testing for Safety: Are Impurities a Problem? Testing for Safety: Are Impurities a Problem? Five of them used an age verification form , which is in compliance with the FDA age requirements and state laws, where the customer has to upload a photo of a government ID, and the other required a signature on delivery of the package.
Therefore, the AAFP advocates for further research into the overall safety and health effects of recreational use, as well as the effects of those laws on patient and societal health. The AAFP supports requirements testing current marijuana and cannabinoid products for safety, dosing, and product consistency. In the Exam Room.
Drug Enforcement Administration (the “DEA”), the U.S. state and federal law to U.S. hemp (including CBD) products and the scope of any regulations by the U.S. Food and Drug Administration (the “FDA”), the U.S. Federal Trade Commission (the “FTC”), the U.S. hemp industry in the U.S.,
The Vertical Bliss case is one of the first massive enforcement actions since the implementation of licensing under the Medical and Adult-Use Cannabis Regulation and Safety Act–late last year, the California Department of Food and Agriculture sued another operator, but not much public enforcement has happened since then.
Many people in the cannabis industry are convinced that this HHS recommendation to the Drug Enforcement Administration (DEA) means that the DEA will undertake this rescheduling (and fairly quickly, too–which would be a huge departure from its refusal to reschedule back in 2016). Just my two cents; feel free to disagree.
One of our primary goals for Meadowlands was to open the channels of communication and make sure compliance and regulatory information are available to everyone in the community who needs it, not just those who can afford compliance experts. We believe in lowering the cost of compliance through free-flowing and accurate information.
According to the CSA (and subsequent regulations ), Schedule I substances have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. Presumably, these requirements provided justification for the DEA to burden these religious exemptions.
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision.
Back in August 2020, the Drug Enforcement Administration (the “DEA”) released its Interim Final Rule (the “ IFR” ) in which the agency stated, in part, that “[a]ll synthetically derived tetrahydrocannabinols remain schedule I controlled substances.” This chemical conversion is at the root of the legal confusion.
To learn more about telehealth appointments and CannaMD ‘s COVID-19 safety measures, see: Coronavirus Policies. In accordance with state law, all CannaMD doctors hold an active, unrestricted license as either an allopathic physician or osteopathic physician and are in compliance with all state-mandated education requirements.
The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. Emphasis added). State-compliant cannabis activity would no longer violate federal criminal law.
The enforcement role moves from DEA to ATF. When it comes to enforcing federal cannabis regulations, the Drug Enforcement Administration (“DEA”) is out and the Bureau of Alcohol, Tobacco, Firearms, and Explosives (“ATF”) is in (in addition to TTB as the primary overseer). .
“FDA is aware that companies market products containing cannabis and cannabis-derived compounds in ways that violate the law and may put consumer health and safety at risk.”. Questions remain regarding the safety of these compounds,” it continued. Trump included a similar request in prior budgets , but Congress rejected the cuts.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content